Lacosamide Sandoz

Lacosamide, the active ingredient in Lacosamide Sandoz, is a sodium channel blocker presented as a tablet for oral use. It is employed as an antiepileptic medication to provide adjunctive therapy for partial‑onset seizures in patients who require additional seizure control.

GNH USA supplies Lacosamide Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution. The product is manufactured under strict GMP conditions and is available for bulk and unit‑dose orders.

Lacosamide is an antiepileptic that modulates voltage‑gated sodium channels, stabilizing neuronal membranes and thereby reducing the frequency of seizure activity in patients with focal epilepsy.

Partial‑onset seizures: provides adjunctive seizure control when added to existing antiepileptic therapy. Adjunctive therapy in focal epilepsy: helps reduce overall seizure burden when combined with other antiepileptic drugs.

Lacosamide may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Dizziness - Nausea - Fatigue - Headache - Blurred vision - Somnolence

Serious or Rare Side Effects: - Cardiac arrhythmias (e.g., PR interval prolongation) - Suicidal ideation or behavior - Severe skin reactions such as Stevens‑Johnson syndrome - Respiratory depression - Elevated liver enzymes - Anaphylactic reactions

When prescribing Lacosamide, clinicians should consider several safety aspects.

Renal impairment: monitor renal function and adjust therapy as needed. Hepatic impairment: assess liver enzymes regularly. Cardiac conduction disorders: obtain baseline ECG and monitor for PR‑interval changes. Pregnancy: risk category unknown; discuss potential benefits and risks with the patient. Concomitant CNS depressants: may increase sedation and respiratory depression. Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Lacosamide can interact with other medicines, requiring attention to dosing and monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampicin): may reduce lacosamide effectiveness. - Class I antiarrhythmic agents: additive effects on cardiac conduction.

Moderate Interactions (Monitor Closely): - Carbamazepine: may alter lacosamide levels. - Alcohol: can enhance central nervous system depression. - Other antiepileptic drugs: may require dose adjustments based on therapeutic response.